The global fanconi anemia drug market is anticipated to grow at a significant CAGR of 5.1% during the forecast period. The rising incidence of blood diseases globally is acting as one of the prime factors affecting and driving the market's expansion. As per the information provide by Cleveland Clinic in 2020, anemia had affected more than two billion people across the globe which accounts for more than 30% of the global population. It is more widespread in resource-poor countries, however, it also affects many people in developed countries. Anemia is the most frequent blood disorder in the US and the condition affects an estimated three million people in US. Moreover, the market is further influenced by continual technological improvements that support providing effective treatment and an increase in government activities to raise awareness.

Impact of COVID-19 Pandemic on Global Fanconi Anemia Drug Market

The COVID-19 pandemic had impacted the global fanconi anemia drug market significantly owning to the lockdown restrictions in most nations to control the spread of the virus and the supply chain interruptions. However, the COVID-19 pandemic had a favorable impact on the global fanconi anemia market. As immunosuppression increases the risk of infection and problems in persons getting active treatment for fanconi anemia, it may be advantageous if it minimizes the late destruction of hyperinflammatory tissue. As a result, the COVID-19 pandemic is expected to drive the fanconi anemia market.

Segmental Outlook 

The global fanconi anemia drug market is segmented based on type and application. Based on the type, the market is sub-segmented into eltrombopag olamine, EXG-34217, and fancalen. Based on the application, the market is sub-segmented into the hospital & clinic, and laboratories. Among these Eltrombopag olamine segment is growing as it is used to treat aplastic anemia in extreme cases and fanconi anemia is also a form of anaplastic anemia. Eltrombopag olamine binds to the thrombopoietin receptor, which stimulates platelet production in the bone marrow. 

Global Fanconi Anemia Drug Market Share by Application, 2021 (%) 

The Hospital & Clinic Segment Holds the Prominent Share in the Global Fanconi Anemia Drug Market

Based on the application, the hospital & clinic holds a significant share in the global fanconi anemia drug market as hospital & clinic is a specialized area that is integrated into the care of the medical center. These include centers such as a hospital, outpatient clinics, drug-dependent facilities, and poison control centers. Additionally, due to the growth in the geriatric population and the rising prevalence of fanconi anemia, hospital pharmacies are likely to grow which in turn is supporting the growth of the segment in the market.

Regional Outlooks

The global fanconi anemia drug market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East & Africa, and Latin America). Among the regions, the Asia Pacific is anticipated to hold a significant share in the market followed by North America, and then Europe.

Global Fanconi Anemia Drug Market Growth, by Region 2022-2028 

The Asia-Pacific Region Expected to Hold Considerable Share in the Global Fanconi Anemia Drug Market

Asia-Pacific region holds a significant share and is anticipated to grow prominently during the forecast period in the fanconi anemia drug market. The presence of emerging countries such as China, Japan, India, and South Korea are taking big initiatives to fuel up the overall fanconi anemia drug anemia market. Due to its big population and rapid development of healthcare technology, Asia-Pacific is likely to account for a significant market share in the fanconi anemia drug market. Furthermore, increasing demand for quality devices in healthcare is projected to lead to the use of advanced equipment, which, in turn, will increase the market growth of the acquired aplastic anemia in the region.

Market Players Outlook

The major companies serving the global fanconi anemia drug market include Abeona Therapeutics Inc., Genethon SA. Novartis AG, Elixigren Therapeutics, Inc. and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in December 2021, Rocket Pharmaceuticals, Inc. announced positive clinical updates from its ongoing Phase 2 registrational trials for Fanconi Anemia (FA) and Leukocyte Adhesion Deficiency-I (LAD-I), along with its ongoing Phase 1 trial for Pyruvate Kinase Deficiency (PKD).

The Report Covers

• Market value data analysis of 2021 and forecast to 2028.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global fanconi anemia drug market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.